Deerfield, IL – According to filings with the U.S. Securities and Exchange Commission, Aerami Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Steven Thornton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aerami Therapeutics

Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our platform is designed to overcome the limitations of injectable, oral, and other inhaled formulation technologies for managing severe respiratory and chronic diseases. Ultimately, our aim is to improve treatment efficacy and improve patient lives.

To learn more about Aerami Therapeutics, visit http://aerami.com/

Contact:
Steven Thornton, Chief Executive Officer
919-589-7495
https://www.linkedin.com/in/steve-thornton-7a402865/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved